Results 31 to 40 of about 23,348 (143)

Anti-oxidants in Parkinson's disease therapy: a critical point of view [PDF]

, 2016
Parkinson's disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the SubstantiaNigra.
Beltramini, Mariano, Bisaglia, Marco, Bubacco, Luigi, Filograna, Roberta   +3 more
core   +2 more sources

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

Journal of Lipid Research, 2010
Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol, but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apolipoprotein (apo)A-I gene and ...
Lin-Hua Zhang, Vaijinath S. Kamanna, Shobha H. Ganji, Xi-Ming Xiong, Moti L. Kashyap   +4 more
doaj   +1 more source

Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin

Scientific Reports, 2023
Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM).
Hsin-Chung Lin, Chi-Hsiang Chung, Lih-Chyang Chen, Jui-Yang Wang, Chien-Chou Chen, Kuo-Yang Huang, Ming-Hang Tsai, Wu-Chien Chien, Hsin-An Lin   +8 more
doaj   +1 more source

Effects of Pioglitazone on Stearoyl-CoA Desaturase in Obese Zucker fa/fa Rats

Journal of Pharmacological Sciences, 2007
The effects of a peroxisome proliferator activated receptor γ (PPARγ) agonist on hepatic stearoyl-CoA desaturase (SCD) in insulin-resistant and obese Zucker fa/fa rats were studied.
Tomoaki Toyama, Naomi Kudo, Yasuhide Hibino, Atsushi Mitsumoto, Masazumi Nishikawa, Yoichi Kawashima   +5 more
doaj   +1 more source

The Effect of Co-administration of Pioglitazone and Simvastatin on Insulin Resistance Parameters and PPAR.γ Expression in Insulin-resistant Rats [PDF]

Journal of Kerman University of Medical Sciences, 2017
Backgrounds: Insulin resistance is a pathological condition associated with metabolic syndrome. In this condition, insulin action in liver, muscles, and adipocytes decreases which leads to hyperglycemia, hyperinsulinemia, and dyslipidemia ...
Gholam Abbas Mohammadi, Behnaz Danesh, Hosein Fallah, Samaneh Rahemi   +3 more
doaj  

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

Cardiovascular Diabetology, 2017
Background and aims Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary ...
Marit de Jong, H. Bart van der Worp, Yolanda van der Graaf, Frank L. J. Visseren, Jan Westerink   +4 more
doaj   +1 more source

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]

Diabetes & Metabolism Journal, 2016
BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim   +16 more
doaj   +1 more source

PPARγ agonist-loaded PLGA -PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies [PDF]

, 2018
Objective: The first aim of this study was to develop a nanocarrier that could transport the peroxisome proliferator-activated receptor agonist, pioglitazone (PGZ) across brain endothelium and examine the mechanism of nanoparticle transcytosis.
Benito, Pol Andres, Calpena, Ana Cristina, Espina, Marta, Ferrer, Isidre, Garcia, Maria Luisa, Gromnicova, Radka, Male, David, Roig-Carles, David, Romero, Ignacio A., Silva-Abreu, Marcelle   +9 more
core   +1 more source

Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan

Emergency Medicine International, 2021
Background. Pioglitazone use via the PPARγ agonist in sepsis patients is inconclusive. It was based on a great number of animal studies. However, except for information from animal studies, there are merely any data of human studies for reference ...
Ming-Shun Hsieh, Sung-Yuan Hu, Shu-Hui Liao, Chia-Ming Chang, Vivian Chia-Rong Hsieh, Chorng-Kuang How   +5 more
doaj   +1 more source

Treating hepatic steatosis and fibrosis by modulating mitochondrial pyruvate metabolism [PDF]

, 2019
A hepatic comorbidity of metabolic syndrome, known as nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence in conjunction with the pandemics of obesity and diabetes.
Finck, Brian N, McCommis, Kyle S
core   +2 more sources